Bladder Cancer
Pipeline by Development Stage
Drug Modality Breakdown
Bladder Cancer is a $5.0B market that is mature and consolidating, dominated by off-label use of products approved for other indications.
Key Trends
- Market heavily skewed toward androgen receptor antagonists (52% share) and multi-kinase inhibitors, neither primarily indicated for bladder cancer
- Limited primary-indication pipeline activity suggests bladder cancer is undersupported relative to market size
- Immunotherapy checkpoint inhibitors (PD-1/PD-L1) gaining traction but remain secondary indications
Career Verdict
Bladder cancer specialization is strategically risky due to off-label product dominance, limited primary-indication innovation, and upcoming patent cliffs; consider only if focused on immunotherapy or precision oncology niches.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | XTANDI (enzalutamide) | Astellas | $2.6B | 52% | Peak | Stable | 10.7yr |
| 2 | CABOMETYX (cabozantinib) | Exelixis | $1.1B | 22% | Peak | Stable | 7.2yr |
| 3 | LYNPARZA (olaparib) | AstraZeneca | $487M | 10% | Peak | Growing | 5.2yr |
| 4 | KORLYM (mifepristone) | Corcept Therapeutics | $229M | 5% | Peak | Stable | 12.2yr |
Drug Class Breakdown
off-label dominance
secondary indication
emerging in biomarker-selected populations
niche indication
expanding in immunotherapy trials
Career Outlook
StableBladder cancer is a mature, consolidating market with limited primary-indication innovation and heavy reliance on off-label products, creating both stability and stagnation. Entry into this space is best suited for professionals with immunotherapy, precision oncology, or biomarker expertise rather than general oncology. Long-term career growth is constrained unless you position yourself in adjacent therapeutic areas (e.g., first-line urothelial cancer immunotherapy) or in clinical trial design for repositioning trials.
Breaking In
Join a major oncology company (AstraZeneca, J&J, Merck, Roche) in a clinical operations or medical affairs role; avoid pure commercial-only positions in a mature market without differentiation.
For Experienced Professionals
Transition toward immunotherapy pipeline roles or seek positions in biomarker-driven precision oncology where bladder cancer expertise adds genuine competitive advantage; do not rely on primary-indication growth.
In-Demand Skills
Best For
Hiring Landscape
6,152 total jobs across 15 companies, with heavy concentration in Commercial (1,233 roles at $257K avg) and Manufacturing (556 roles). AstraZeneca and Johnson & Johnson lead hiring, though job growth in bladder cancer specifically is unclear due to off-label product portfolio. Clinical Operations roles command highest salary ($307K), reflecting specialized oncology needs.
Top Hiring Companies
By Department
Hiring is robust at major oncology companies, but bladder cancer-specific roles are limited; maximize earning potential through Clinical Operations or R&D specialization.
Competitive Landscape
73 companies ranked by most advanced pipeline stage
+43 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 6,312 patients across 50 trials
A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.
Recurrence of Bladder Cancer After Transurethral Resection With Hexvix
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer
Immunological Response of Bladder Cancer Patients Under BCG
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer
Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer
Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
Related Jobs in Oncology
Associate Director, Oncology Lifecycle Management - Hematologic Oncology
Senior Oncology Account Specialist Genitourinary Spokane, WA
Value and Evidence, Field Director
Cheffe / Chef de Produits Junior Médecine de la Reproduction en alternance
Senior Oncology Account Specialist Genitourinary Long Island, NY
Key Account Manager, Uro-Oncology – Boston, MA
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.